ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
- Revenue, 2025
- $3.7B
- YoY, 2025
- +65.2%
- 5-year CAGR
- +49.8%
Revenue
Revenue by fiscal year
| Period | Revenue | YoY |
|---|---|---|
| 2025 | $3.7B | +65.2% |
| 2024 | $2.2B | +23.0% |
| 2023 | $1.8B | +76.2% |
| 2022 | $1.0B | +22.9% |
| 2021 | $844M | +71.3% |
| 2020 | $493M | +124.3% |
| 2019 | $220M | +193.4% |
| 2018 | $75M | −16.7% |
| 2017 | $90M | +90.7% |
| 2016 | $47M | — |
| 2010 | $100M | −0.5% |
| 2009 | $101M | +4.5% |
| 2008 | $96M | — |